KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Receivables: 2010-2025

Historic Change in Receivables for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Sep 2025 value amounting to $51.0 million.

  • Jazz Pharmaceuticals' Change in Receivables rose 129.13% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.6 million, marking a year-over-year decrease of 59.36%. This contributed to the annual value of $21.1 million for FY2024, which is 59.30% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Change in Receivables of $51.0 million as of Q3 2025, which was down 8.15% from $55.5 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Change in Receivables' 5-year high stood at $75.5 million during Q4 2023, with a 5-year trough of -$66.0 million in Q1 2025.
  • Its 3-year average for Change in Receivables is $10.3 million, with a median of $8.4 million in 2024.
  • Examining YoY changes over the last 5 years, Jazz Pharmaceuticals' Change in Receivables showed a top increase of 736.69% in 2025 and a maximum decrease of 882.29% in 2025.
  • Jazz Pharmaceuticals' Change in Receivables (Quarterly) stood at $64.8 million in 2021, then declined by 28.58% to $46.3 million in 2022, then surged by 63.11% to $75.5 million in 2023, then tumbled by 101.14% to -$864,000 in 2024, then soared by 129.13% to $51.0 million in 2025.
  • Its Change in Receivables stands at $51.0 million for Q3 2025, versus $55.5 million for Q2 2025 and -$66.0 million for Q1 2025.